Abstract 102P
Background
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths. This study aimed to identify new prognostic and therapeutic targets with particular focus on the extracellular matrix pathway.
Methods
This study aimed to provide a comprehensive analysis of the Collagen type IX alpha 1 chain (COL9A1) from a pan-cancer perspective employing multiomics data followed by validation in an additional cohort of CRC. The expression profile and function of COL9A1across different tumors were investigated to investigate the expression profile, genomic alterations, survival analysis, protein-protein interaction, correlation with immune cell subtypes, tumor immune microenvironment and enrichment analysis. Among the high top-score genes and dysregulated pathways associated with CRC, COL9A1 was detected and further validated in 120 CRC patients. Ccollagen family members were identified as core upregulated genes through protein-protein interaction network analysis followed by validation of expression and mutation analysis using RT-PCR and whole exome sequencing in CRC patients.
Results
Collagen family members were identified as core upregulated genes through PPI network analysis. The pan-cancer analysis demonstrated the consistent upregulation of COL9A1 across various cancers, including CRC. Moreover, the study explored the correlations between COL9A1 and immune infiltration to evaluate its potential as a therapeutic target and a guide for clinical treatment. The findings suggest that increased COL9A1 expression is associated with poorer overall and disease-free survival outcomes. The levels of COL9A1 promoter methylation were decreased.Functional enrichment analysis highlighted the critical role of COL9A1 in essential pathways, further underscoring its prognostic significance in CRC.
Conclusions
This study illustrated the comprehensive evidence supporting the importance of COL9A1 in the development and prognosis of CRC.
Clinical trial identification
N?A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.